Safety and efficacy of remimazolam versus propofol in aneurysm coil patients

Safety and efficacy of remimazolam versus propofol in aneurysm coil patients using I-gel insertion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008196

Enrollment

108

Registered

2023-02-16

Start date

2023-02-02

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients in this study are randomly assigned to the Propofol group (active control group, P group) or the Remimazolam group (test group, R group) by a computer-generated random number table. In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 19-65 years patients who are scheduled for unruptured-aneurysm coil embolization

Exclusion criteria

Exclusion criteria: BMI > 30 kg/m2 Anticipated difficult airway Anticipated difficult mask ventilation COPD, astham, pneumonia, active URI Risk of aspiration Patients unable to response on verbal command History of allergies to benzodiazepines History of allergies to opioids History of substance abuse/addiction Pregnant or breastfeeding patients

Design outcomes

Primary

Measure	Time frame
the difference between maximum arterial blood pressure and minimum arterial blood pressure	—

Secondary

Measure	Time frame
time to eye opening, recall, nasea, vomiting, pain	—

Countries

Korea, Republic of

Contacts

Public ContactJuyeon Oh

Ajou University Hospital

itisamy@hanmail.net+82-31-219-4916

Outcome results